Overview

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

Status:
Completed
Trial end date:
2018-04-05
Target enrollment:
Participant gender:
Summary
A study to assess the safety, tolerability, and pharmacokinetics of AMG 986 given orally as a single dose to healthy participants and participants with severely impaired kidney function.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen